Wixela Inhub: A Generic Equivalent Treatment Option for
WEBDec 7, 2020 · Fluticasone propionate/salmeterol dose strengths for Wixela Inhub and Advair Diskus are comparable. The bioequivalence demonstrated supports the use of Wixela Inhub and provides a treatment option for patients with asthma or COPD.
Hikma launches generic Advair Diskus® following FDA approval
WEBLondon, 17 December 2020 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline’s Advair Diskus® [1] (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.
WEBThis NDA provides for the use of hydromorphone hydrochloride injection, for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate....
Hikma, Vectura team up to target GSK respiratory drugs
WEBNov 8, 2018 · Hikma says interactions with the FDA have led the companies to believe that Vectura’s Open-Inhale-Close dry powder inhaler device can win the agency’s blessing as generic copies to GSK’s Ellipta products. Vectura will be responsible for developing the formulation for the products.
Vectura earns $11m milestone as Hikma receives US FDA …
WEBDec 17, 2020 · Vectura Group plc (LSE: VEC) (“Vectura”), an industry-leading specialist inhalation CDMO, today announces that its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus®1 (fluticasone propionate and salmeterol inhalation powder), 100mcg/50mcg and 250mcg/50mcg doses, in the US.
Hyloris Announces Major Commercial Partnership in the U.S.
WEBApr 28, 2021 · Hikma Pharmaceuticals, a leading supplier of complex, injectable hospital products in the U.S., to commercialise Maxigesic IV in the U.S.
WEBJun 19, 2006 · Infections of the Skin and Skin Structure: Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) isolates of Streptococcus spp. (α- and β-hemolytic …
INFLACOX - Drug - RxReasoner
WEBThe drug INFLACOX contains one active pharmaceutical ingredient (API): 1 Celecoxib. UNII JCX84Q7J1L - CELECOXIB. Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily).
Global agreement with Hikma to develop generic versions of ... - Vectura
WEBVectura Group today announces signing an agreement with Hikma Pharmaceuticals for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder inhaler device.
Hikma to ease U.S. hydromorphone shortage; FDA gives ... - Fierce …
WEBJul 18, 2018 · Generics maker Hikma is looking to ease the U.S. shortage of hydromorphone with increased production as the FDA gave its OK to Terumo BCT to shore up short supplies of anticoagulant solution.